Potential Biomarkers for Early Gastric Cancer Detection
Author Information
Author(s): Oh Sooyeon, Lee Sang-Soo, Jin Hoeyoung, Choi Seo-Hyeon, Cha Choong-Keun, Lee Jooho, Kwack KyuBum, Kim Sang Gyun, Choi Sang-Woon
Primary Institution: Seoul National University Hospital and CHA University School of Medicine
Hypothesis
ADAMs and MICA may serve as biomarkers for screening early gastric cancer.
Conclusion
ADAM12, ADAM17 mRNA, and ADAM10 protein levels in blood could be potential biomarkers for early gastric cancer screening.
Supporting Evidence
- ADAM12, ADAM17 mRNA, and ADAM10 protein levels were significantly elevated in patients with early gastric cancer compared to controls.
- Receiver-operating characteristic analysis showed promising areas under the curve for the biomarkers.
- Previous studies indicated that ADAMs are upregulated in gastric cancer tissues.
Takeaway
Doctors are looking for new ways to find stomach cancer early, and this study found that certain proteins in the blood might help with that.
Methodology
The study used in-silico analysis and blood sample testing to evaluate the expression of ADAMs and MICA in gastric cancer.
Potential Biases
Potential bias due to small sample size and lack of matching in participant demographics.
Limitations
The sample size was small, and age and sex matching could not be done.
Participant Demographics
The study included 27 patients with early gastric cancer and 30 healthy controls, with a majority being men.
Statistical Information
P-Value
p=0.0007 for ADAM12, p<0.0001 for ADAM17, p<0.001 for ADAM10
Confidence Interval
95% CI: 0.6334 to 0.8802 for ADAM12, 95% CI: 0.6889 to 0.9234 for ADAM17, 95% CI: 0.6895 to 0.9320 for ADAM10
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website